Rigel Pharmaceuticals/RIGL

$1.47

-5.16%
-
1D1W1MYTD1YMAX

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in discovering, developing and providing therapies that improve the lives of patients with hematologic disorders and cancer. The Company's lead product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its product also includes REZLIDHIA (olutasidenib) capsules, which are for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Its other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development. In addition, it has product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi).

Ticker

RIGL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Raul Rodriguez

Employees

155

Headquarters

South san francisco, United States

RIGL Metrics

BasicAdvanced
$270.27M
Market cap
-
P/E ratio
-$0.14
EPS
0.95
Beta
-
Dividend rate

What the Analysts think about RIGL

Analyst Ratings

Majority rating from 6 analysts.
Hold

Price Targets

Average projection from 6 analysts.
180.95% upside
High $15.00
Low $1.00
$1.47
Current price
$4.13
Average price target

RIGL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-19.92% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$28.1M
4.85%
Net income
$-5.6M
-15.15%
Profit margin
-19.92%
-19.09%

RIGL Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 57.75%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
$0.01
-$0.08
-$0.04
-$0.03
-
Expected
-$0.11
-$0.10
-$0.08
-$0.07
-$0.03
Surprise
-108.92%
-17.95%
-48.72%
-57.75%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Rigel Pharmaceuticals stock

Buy or sell Rigel Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing